Effect of COVID-19 vaccination on the timing and flow of menstrual periods
A new Imperial study has found that periods can be slightly delayed following a COVID vaccination but return to normal the following cycle.
New collaborative research project to advance cancer therapies
Researchers from Imperial are collaborating with RemedyBio on a novel tumour infiltrating lymphocyte (TILs) discovery approach.
New study shows 95% of new cancer drugs are approved in the US before Europe
Over the last decade, the US FDA is faster to approve new oncology therapies compared with the European EMA; but that speed may have consequences.
Highlighting uncertainty in emergency bowel surgery prediction models
Imperial researchers have created a new model that highlights uncertainty when predicting the risk of death in emergency bowel surgery.
Treatments for varicose veins
A new multicentre randomised clinical trial has compared two different treatment methods for varicose veins.
Kisspeptin reduces liver damage in non-alcoholic fatty liver disease in mice
New research finds that a hormone previously linked to attraction may have the potential to treat liver disease.
Cancer Research UK renew support for Convergence Science Centre
Renewed funding will continue uniting cancer researchers with engineers and physical scientists to tackle cancer’s toughest challenges.
New funding to tackle healthy ageing
Researchers at 28 UK universities, including Imperial, have received funding to tackle healthy ageing.
Antiviral metabolite identified as potential serum biomarker for viral infection
A new paper from Imperial scientists has identified an antiviral metabolite as a potential serum biomarker for viral infections, including SARS-CoV-2.
Microbiome signature for ischaemic heart disease unravelled
New international studies have characterised the imbalanced gut bacteria of patients with myocardial infarction, angina and heart failure.
